FDA approves second drug for Alzheimer’s disease
Leqembi has been given the green light, after the controversial approval in 2021 of Aduhelm
The US Food and Drug Administration has approved a second drug for Alzheimer’s disease, lecanemab (Leqembi), despite reports of rare brain bleeds linked to use of the drug in some patients.
Leqembi, made by Eisai and marketed by Biogen, will be only the second drug for Alzheimer’s disease to receive FDA approval in the past 18 months.
